1 Prescribing pre-exposure prophylaxis (PrEP) for HIV prevention: A cross-sectional survey

2 of General Practitioners in Australia

- 3 Jason Wu^{1,2}, Christopher K. Fairley^{2,3}, Daniel Grace⁴, Benjamin R. Bavinton⁵, Doug Fraser⁵,
- 4 Curtis Chan⁵, Eric P.F. Chow^{2,3,6*}, Jason J. Ong^{2,3,6,7*}
- 5
- ⁶ ¹ Kings Park Medical Centre Hillside, General Practice, Melbourne, Vic., Australia
- 7 ² Melbourne Sexual Health Centre, Alfred Health, Melbourne, Vic., Australia
- 8 ³ Central Clinical School, Monash University, Melbourne, Australia
- 9 ⁴ University of Toronto, Dalla Lana School of Public Health, Toronto, Canada
- ⁵ Kirby Institute, The University of New South Wales, New South Wales, Australia
- ⁶ Melbourne School of Population & Global Health, The University of Melbourne, Melbourne,
- 12 Australia
- ¹³⁷ Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine,
- 14 London, United Kingdom
- 15 * Co-senior authors
- 16
- 17 Corresponding author
- 18 Jason Wu
- 19 40 Gourlay Road,
- 20 Hillside VIC 3037.
- 21 Phone: +613 9217 9400
- 22 Email: jasun_quo@hotmail.com

- 24
- 25

26 ABSTRACT

27

28 Background

- 29 Pre-exposure prophylaxis (PrEP) is a safe and effective medication for preventing HIV
- 30 acquisition. We examined Australian general practitioners' (GP) knowledge of PrEP efficacy,
- 31 characteristics associated with ever prescribing PrEP, and barriers to prescribing.

32 Methods

- 33 We conducted an online cross-sectional survey of GPs working in Australia between April and
- 34 October 2022. We performed univariable and multivariable logistic regression analyses to
- identify factors associated with: 1) the belief that PrEP was at least 80% efficacious; and 2)
- 36 ever prescribed PrEP. We asked participants to rate the extent to which barriers affected their
- 37 prescribing of PrEP.

38 Results

- 407 participants with a median age of 38 years (interquartile range 33-44). Half of the
- 40 participants (50%, 205/407) identified how to correctly take PrEP, 63% (258/407) had ever
- 41 prescribed PrEP, and 45% (184/407) felt confident with prescribing PrEP. Ever prescribing
- 42 PrEP was associated with younger age (AOR 0.97, 95%CI: 0.94-0.99), extra training in sexual
- 43 health (AOR 2.57, 95%CI: 1.54-4.29), and being a S100 Prescriber (OR 2.95, 95%CI: 1.47-
- 5.90). The main barriers to prescribing PrEP included: 'Difficulty identifying clients who
- require PrEP/relying on clients to ask for PrEP' (76%, 310/407), 'Lack of knowledge about
- 46 PrEP' (70%, 286/407), and 'Lack of time' (69%, 281/407).

47 Conclusion

Less than half of our GP respondents were confident in prescribing PrEP, and most had
difficulty identifying who would require PrEP. Specific training on PrEP, which focuses on
PrEP knowledge, identifying suitable clients, and making it time efficient is recommended,
with GPs being remunerated for their time.

- 52
- 53
- 54
- 55

56 **INTRODUCTION**

57

58 Studies have shown that pre-exposure prophylaxis (PrEP) is up to 99% effective at reducing 59 HIV infection by sexual transmission and is safe (1, 2). The Joint United Nations Programme 60 on HIV/AIDS (UNAIDS) has set a declaration to end the AIDS epidemic by 2030, and one of 61 the targets to accomplish this goal is to ensure the availability of PrEP for 10 million people 62 at substantial risk of HIV by 2025 (3).

63

64 Most GPs in Australia have no or limited experience in HIV treatment and prevention. There were 39,736 GPs working in Australia in 2022/23 (4), and as of January 2024 there are only 65 265 HIV S100 prescribers (able to prescribe HIV treatment) with only a proportion of these 66 67 being GPs (5). There are only 114 sexual health physicians working in Australia, with the majority working in major cities (6). Any doctor or nurse practitioner in Australia can 68 prescribe PrEP, which has been on the Australian government's Pharmaceutical Benefits 69 70 Scheme (PBS) since April 2018. The PBS subsidises the cost of certain medications so that 71 PrEP costs AU\$30 for 30 pills or \$7.30 for people with a concession card. There have been 18,217 individual prescribers who have prescribed PrEP in Australia (7). 72

73

Past studies have identified several barriers to PrEP prescribing among GPs. Barriers include lack of knowledge regarding PrEP, inability to identify clients at risk of HIV, and concern that PrEP use may increase the incidence of other STIs (8, 9, 10, 11, 12). An Australian GP questionnaire found the main barriers to PrEP prescribing were lack of experience with antiretrovirals and lack of guidelines for prescription (13). Another Australian study involving interviews with 51 healthcare professionals identified barriers such as attributing PrEP to 'promiscuity' and a belief that condom use was satisfactory HIV prevention (14).

81

These studies on PrEP perspectives among health professionals were either qualitative or were conducted before PrEP was available on the PBS for GPs to prescribe. We sought to conduct a quantitative study looking at GP knowledge of PrEP, confidence with prescribing and the barriers to prescribing.

86

87 METHODS

88

89 Study population and recruitment

We distributed this anonymous online survey to GPs, GP registrars and trainees in Australia 90 between April 14th and October 13th, 2022. Participants were eligible if they lived in 91 92 Australia. Other exclusion criteria included having answers that were unusual for the 93 question, and if <90% of the questions were answered. The survey link was disseminated via a Facebook group for Australian GPs, the Royal Australian College of General Practitioners, 94 Melbourne Sexual Health Centre and Public Health Networks. This was a voluntary survey, 95 and completion of the survey implied consent. Participants could opt-in to win one of five 96 97 \$300 vouchers. 98 99 Survey instrument Respondents accessed the survey through an online link (hosted by Qualtrics). We utilized a 100 KAP (Knowledge, Attitudes and Practices) survey model to structure our questions (15). The 101 survey collected data on sociodemographic characteristics and assessed their knowledge of 102 103 PrEP. Respondents were given five options for each question, with the complete questions

and options listed in Supplementary File 1.

105

Respondents were asked how likely they were to prescribe PrEP to hypothetical clients from
certain groups, with responses as a Likert scale (not at all, unlikely, likely, highly likely,
certain). The groups included: *Sexually active males who have anal sex with males without*condoms', *Sexually active males who have anal sex with males and report condom use'*, *Sexually active heterosexual males and females at increased risk of HIV transmission'*, *People who inject drugs'*, *Serodiscordant couples (i.e. one partner HIV positive and the*

other HIV negative)', and 'Sex workers'. These questions were adapted from an Australian
study (13).

114

115 They were also asked how much certain barriers affect their ability to prescribe PrEP, with 116 responses as a Likert scale (not affected, slightly affected, moderately affected, very

affected, unsure). The barriers included 'Lack of knowledge about PrEP', 'Lack of time to 117 adequately counsel about PrEP', 'Unsure where to look for resources on PrEP', 'Resources on 118 PrEP difficult to use/interpret', 'Difficulty identifying which clients would require PrEP / 119 relying on clients to ask for PrEP', 'Lack of experience or hesitation in prescribing antivirals', 120 'Difficulty in finding an entry point to asking clients about their risk of HIV/sexual history', 121 'Concern that promoting PrEP may increase risk of other STIs', 'Concern that the client may 122 not take PrEP properly / be non-compliant', 'Discomfort with managing people who identify 123 as LGBTIQ'. Respondents were also allowed to list other barriers via free text entry. 124 125 There were additional questions about how often GPs prescribed PrEP, how confident they 126 felt when prescribing, and how often they took clients' sexual history, with full details in

127 Supplementary File 1.

128

129 Statistical analysis

We used descriptive statistics to summarise the characteristics of the study participants. 130 Logistic regression analyses were used to identify factors associated with two outcomes: 1) 131 belief that PrEP was at least 80% efficacious; and 2) ever prescribed PrEP. Variables were 132 initially included in the multivariable model if the p value was <0.20 in the univariable analysis. 133 Using complete case analysis, we used a backward elimination approach to derive the final 134 multivariable model. We reported both crude and adjusted odds ratio, 95% confidence 135 136 interval. Statistical significance was defined as having a p value of <0.05. Statistical analyses 137 were performed using Stata (version 17, StataCorp, College Station, TX).

138

139 **Ethics approval**

140 Ethics approval was obtained from the Alfred Ethics Committee, Melbourne, Australia141 (166/22).

142

143

144 **RESULTS**

We received 703 survey respondents, but 90 were excluded as they had answers that were 145 unusual e.g. a question asking about barriers to PrEP prescribing yielded an answer of 'The 146 prediction method of the expanded algorithm'. A further 171 were excluded as they were 147 148 completed in countries outside Australia, and 35 were excluded because the number of questions answered was <90%. The sociodemographic characteristics of the 407 participants 149 are detailed in our other study (16). Briefly, the median age of the participants was 38, with 150 151 an interquartile range (IQR) of 33-44. The median years of practising as a GP was 6, with an IQR of 4-12. 152

153

154 Test of Knowledge

Only 50.4% (205/407) of participants could identify how to correctly take PrEP, which was
selecting the response: 'taking a pill daily for 7 days before an HIV exposure and then
ongoing for at least 28 days'. There were 24.8% (101/407) of respondents unsure of how
effective PrEP was at preventing HIV, while 68.8% (280/407) correctly identified that PrEP is
>80% effective at preventing HIV.

160

161 **Prescribing practices**

About two-thirds (63.4%, 258/407) of GPs had ever prescribed PrEP. Only 45.2% (184/407) felt confident with prescribing PrEP. The proportion of participants who prescribed PrEP 'less than once a year' was 44.7% (182/407), 'at least once a year' was 13% (53/407), 'at least once every three months' was 18.2% (74/407), 'at least once a month' was 8.8% (36/407), and 'at least once a week' was 9.2% (37/407). Sixty-seven percent (273/407) of participants have had a client ask them for PrEP before. Table 2 outlines when participants last took a sexual history.

168

169 **Prescribing to certain groups**

170 Figure 1 details the proportion of respondents who stated they would be likely, highly likely

171 or certain to prescribe to certain groups. Some notable results include sexually active males

who have anal sex with males without condoms (92.6%, 377/407) and sex workers in

- 173 Australian (74.9%, 305/407).
- 174



175 Figure 1: Likelihood of prescribing PrEP to certain client groups (%).

176

177 MSM = Men who have sex with Men.

- 178
- 179

180 Factors associated with stated efficacy of PrEP > 80% and ever prescribing PrEP.

181 Table 2 demonstrates that efficacy of PrEP >80% was associated with younger age (Adjusted

odds ratio (AOR) 0.97 per additional year of age, 95% confidence interval(CI): 0.94-0.99),

and negatively associated with taking last sexual history 'more than a month ago' (AOR 0.35,

184 95%CI: 0.17-0.71) compared with 'less than a week ago', and positively associated with

185 extra training in in sexual health (AOR 1.83, 95%CI: 1.09-3.06), and S100 prescriber status

186 (AOR 3.38, 95%CI: 1.44-8.00).

187 Table 3 demonstrates that ever prescribing PrEP was negatively associated with increasing

age (AOR 0.96, 95%CI: 0.93-0.98), and positively associated with working in the inner city

189 compared to metropolitan or suburban area (AOR 3.40, 95%CI: 1.65-7.03), with extra

training in sexual health (AOR 2.57, 95%CI: 1.54-4.29) and negatively associated with being a

191 GP in Western Australia (AOR 0.22, 95%CI: 0.09-0.52) compared to Victoria. Most (77.6%,

192 316/407) participants reported PrEP education should be an essential part of HIV education

193 at GP visits.

194Table 2 – Factors associated with stated efficacy of PrEP > 80% (N=371)

| Factors | n/N (%) | Odds ratio (95% CI) | P-value | AOR (95% CI) | P-value |
|-----------------------------|--------------|---------------------|---------|--------------------|---------|
| Age (years) | | 0.97 (0.95 - 1.00) | 0.02 | 0.97 (0.94 - 0.99) | 0.009 |
| Gender | | | | | |
| Female | 183/272 (67) | 1 | | | |
| Male | 75/99 (76) | 1.52 (0.90 - 2.57) | 0.11 | | |
| Location | | | | | |
| Metropolitan or Suburban | 112/174 (64) | 1 | | | |
| Inner City | 59/74 (80) | 2.18 (1.14 – 4.15) | 0.02 | | |
| Regional | 55/77 (71) | 1.38 (0.77 - 2.48) | 0.28 | | |
| Rural | 32/46 (70) | 1.27 (0.63 - 2.55) | 0.51 | | |
| State/territory of practice | | | | | |
| Victoria | 105/146 (72) | 1 | | | |
| New South Wales | 56/78 (72) | 0.99 (0.54 - 1.83) | 0.98 | | |
| Queensland | 37/59 (63) | 0.66 (0.35 - 1.24) | 0.19 | | |
| Western Australia | 22/34 (65) | 0.72 (0.32 - 1.58) | 0.40 | | |
| South Australia | 25/36 (69) | 0.89 (0.40 - 1.97) | 0.76 | | |
| Northern Territory | 4/5 (80) | 1.56 (0.17 - 14.39) | 0.69 | | |
| Tasmania | 9/13 (69) | 0.88 (0.26 - 3.01) | 0.83 | | |

| Duration of practice (years) | | 0.97 (0.95 - 1.00) | 0.05 | | |
|--|--------------|--------------------|-------|--------------------|-------|
| Extra training in sexual health | | | | | |
| No | 145/229 (63) | 1 | | 1 | |
| Yes | 113/142 (80) | 2.26 (1.38 - 3.68) | <0.01 | 1.83 (1.09 - 3.06) | 0.02 |
| S100 prescriber* | | | | | |
| No | 205/311 (66) | 1 | | 1 | |
| Yes | 53/60 (88) | 3.91 (1.72 - 8.91) | <0.01 | 3.38 (1.44 - 8.00) | 0.01 |
| Last sexual history taken from a client: | | | | | |
| Less than a week ago | 192/258 (74) | 1 | | 1 | |
| Less than a month ago | 46/73 (63) | 0.59 (0.34 - 1.02) | 0.05 | 0.66 (0.37 - 1.17) | 0.15 |
| More than a month ago | 20/40 (50) | 0.34 (0.17 - 0.68) | <0.01 | 0.35 (0.17 - 0.71) | <0.01 |

¹⁹⁵ *S100 accreditation allows GPs in Australia to prescribe specialised medications such as antiretrovirals.

AOR = Adjusted odds ratio; CI = confidence interval. Utilised backward elimination approach to derive the final multivariable model.

197 Variables with p-value <0.05 are in bold

198

199

201 Table 3 – Factors associated with ever having prescribed PrEP (N=371)

| Factors | n/N | Odds ratio (95% CI) | P-value | AOR (95% CI) | P-value |
|--------------------------|--------------|---------------------|---------|--------------------|---------|
| Age (years) | | 0.97 (0.94 - 0.99) | 0.01 | 0.96 (0.93 - 0.98) | <0.01 |
| Gender | | | | | |
| Female | 159/272 (58) | 1 | | 1 | |
| Male | 77/99 (78) | 2.49 (1.46 - 4.23) | <0.01 | 2.67 (1.49 - 4.80) | <0.01 |
| Location | | | | | |
| Metropolitan or Suburban | 101/174 (58) | 1 | | 1 | |
| Inner City | 62/74 (84) | 3.73 (1.88 - 7.43) | <0.01 | 3.40 (1.65 - 7.03) | <0.01 |
| Regional | 48/77 (62) | 1.20 (0.69 - 2.07) | 0.52 | 1.14 (0.62 - 2.09) | 0.68 |
| Rural | 25/46 (54) | 0.86 (0.45 - 1.65) | 0.66 | 0.79 (0.38 - 1.65) | 0.54 |
| State | | | | | |
| Victoria | 106/146 (73) | 1 | | 1 | |
| New South Wales | 51/78 (65) | 0.71 (0.39 - 1.29) | 0.26 | 0.74 (0.38 - 1.41) | 0.35 |
| Queensland | 34/59 (58) | 0.51 (0.27 - 0.97) | 0.03 | 0.80 (0.40 - 1.60) | 0.52 |
| Western Australia | 14/34 (41) | 0.26 (0.12 - 0.57) | <0.01 | 0.22 (0.09 - 0.52) | <0.01 |
| South Australia | 20/36 (56) | 0.47 (0.22 - 1.00) | 0.05 | 0.47 (0.21- 1.08) | 0.07 |
| Northern Territory | 3/5 (60) | 0.57 (0.09 - 3.51) | 0.54 | 0.71 (0.10 - 4.93) | 0.72 |
| Tasmania | 8/13 (62) | 0.60 (0.19 - 1.96) | 0.40 | 0.54 (0.15 - 1.92) | 0.34 |

| Duration of Practise (years) | | 0.98 (0.96 - 1.01) | 0.19 | | |
|--|--------------|--------------------|-------|--------------------|-------|
| Extra training in sexual health | | | | | |
| No | 131/229 (57) | 1 | | 1 | |
| Yes | 105/142 (74) | 2.12 (1.34 - 3.35) | <0.01 | 2.57 (1.54 - 4.29) | <0.01 |
| S100 prescriber* | | | | | |
| No | 187/311 (60) | 1 | | | |
| Yes | 49/60 (82) | 2.95 (1.47 - 5.90) | <0.01 | | |
| Last sexual history taken from a client: | | | | | |
| Less than a week ago | 172/258 (67) | 1 | | | |
| Less than a month ago | 43/73 (59) | 0.72 (0.42 - 1.22) | 0.22 | | |
| More than a month ago | 21/40 (53) | 0.55 (0.28 - 1.08) | 0.08 | | |

²⁰² *S100 accreditation allows GPs in Australia to prescribe specialised medications such as antiretrovirals.

AOR = Adjusted odds ratio; CI = confidence interval. Utilised backward elimination approach to derive the final multivariable model.

204 Variables with p-value <0.05 are in bold

205

206

208 Barriers

- 209 Figure 2 details the level of impact of barriers to prescribing PrEP, with the top three
- 210 barriers being: difficulty identifying clients who require PrEP / relying on clients to ask for
- 211 PrEP (76.2%, 310/407), lack of knowledge about PrEP (70.3%, 286/407), and lack of time to
- adequately counsel regarding PrEP (69%, 281/407).
- 213

Figure 2: Level of impact of barriers on GPs and their PrEP prescribing (%).



216 Note that lines do not total to 100% because there was a 5th option for participants: 'Unsure'.

217 PrEP = Pre-exposure prophylaxis; STI = Sexually transmitted infection

218

219 Participants were allowed to write down other barriers that affected their prescribing of

- 220 PrEP or that they could see affecting the prescribing of other doctors. The most common
- written response was problems with knowledge (30.7%, 51/166), followed by lack of clients
- 222 (21.1%, 35/166) and lack of experience (15.1%, 25/166). For details on the other responses,
- refer to Supplementary Figure 1.

224

225 Barriers by the frequency of prescribing

Those who prescribed PrEP 'more often' (more frequent than every 3 months, including 3

227 months) are less likely to be affected by barriers than those who prescribe 'not often' (less

228 frequent than every 3 months). Those who prescribed 'more often' were most affected by

the barriers of lack of time to adequately counsel about PrEP (64.6%, 95/147), difficulty
identifying which patients would require PrEP/relying on the patient to ask for PrEP (64.6%,
95/147), difficulty in finding an entry point to asking patients about their risk of HIV/sexual
history' (47.6%, 70/147). Those who prescribe 'not often' were most affected by the
barriers: lack of knowledge about PrEP (86.8%, 204/235), difficulty identifying which
patients would require PrEP/relying on patients to ask for PrEP (84.7%, 199/235), lack of
experience or hesitation in prescribing antiretrovirals (80.4%, 189/235).

- 236
- 237

238 DISCUSSION

239

240 Our survey of Australian GPs contributes to the literature by demonstrating a significant 241 knowledge gap about PrEP, with only half correctly identifying how to take PrEP. A quarter of participants were unsure how effective PrEP was at preventing HIV. In another Australian 242 study from 2017, only 24% of respondents were able to identify how to take PrEP correctly, 243 and 62% were unsure how effective PrEP was at preventing HIV (13). Our study highlights 244 other areas where GP knowledge of PrEP may be lacking. Three-quarters of participants 245 246 would likely prescribe PrEP to sex workers; however, Australian PrEP guidelines do not identify sex workers as indicated for PrEP (17). Female sex workers have some of the lowest 247 248 HIV rates of any population in Australia, with an incidence rate of <0.1 per 100 person-years 249 (18).

250

Our study found only 45% of participants felt confident about prescribing PrEP, with 35% stating they had never prescribed PrEP before. In contrast, a study of 45 GPs in Australia found that 71% of participants did not feel confident prescribing PrEP and 93% had never consulted a client about PrEP before (13). However, this study was conducted in 2017, before PrEP was on the PBS.

256

The top three barriers that impacted our Australian GPs participants prescribing of PrEP
 were difficulty identifying clients who would benefit from PrEP, lack of knowledge regarding

PrEP, and lack of time to adequately counsel regarding PrEP. These results are comparable 259 with the literature, with the main barriers identified in studies as lack of knowledge 260 regarding PrEP and difficulty identifying clients at risk of HIV (8, 10, 11, 12, 19). Difficulty 261 262 identifying clients who would benefit from PrEP could be addressed by having GP clinics collect certain demographics as part of client registration. Many GP clinics do not have the 263 sexuality of their clients recorded (20). We recommend GP clinics should have questions 264 about clients' sexual identity and the genders of sexual partners in client registration forms. 265 Some potential negative consequences include clients being uncomfortable having this 266 267 information on their medical file, reception staff being aware or if partners found out. It is 268 important the forms have the option of 'choose not to disclose'.

269

270 The other major barrier is lack of time. Assessment and counselling for PrEP can quickly exceed the standard 10-15-minute GP consult. An effective way of increasing the uptake of 271 272 an intervention in GP practice could be creating a specific time-based Medicare item number (21) the main remuneration method for GPs in Australia, with this item being a 273 higher remuneration rate compared to the current item for consults over 20 minutes. 274 However, creating a specific Medicare item can be difficult. A more acceptable solution 275 276 could be short-term practice incentive payments (PIP), e.g. an additional \$10 for every 277 prescription of PrEP, running for 12 months. This can encourage GPs to invest time into 278 learning about PrEP. A UK systematic literature review of 35 articles found payment for performance schemes increased services available and effectively motivated GPs (22). There 279 is a limitation of whether Medicare can identify private scripts of PrEP to award a PIP, as 280 over-seas born MSM are the highest risk groups for HIV (18). Most medical software can 281 282 generate data on scripts, so this could be a way to capture the private PrEP scripts, with the data being sent to Medicare. 283

284

Factors associated with prescribing PrEP were extra training in sexual health or being an S100 prescriber, working in an inner city setting, and younger age. The reason why there is more prescribing in inner-city settings could be due to more sexual health clinics and high caseload GPs being located in these settings. The association with younger age is likely due to going through GP training more recently and being more likely to accept more

progressive ideas. There is a great need for more comprehensive training for GPs regarding
PrEP, assuming no prior knowledge and, in particular, looking at better ways of identifying
clients who would benefit from PrEP. This training should be constructed specifically for the
GP context, taking into account the standard GP consultation time of 10-15 minutes, and
GPs should be remunerated for the training with recommended rate of at least \$200 per
hour of training.

296

PrEP uptake could be increased by having a higher remuneration rate for the existing Telehealth blood borne item number 92734/92737, to allow more Australians including in regional and remote areas, to access PrEP from GPs more confident with PrEP prescribing, and to encourage more GPs to learn about PrEP. Currently these item numbers are at the same remuneration rate as standard Telehealth items for general health issues: \$41.40 for consultation over 6 minutes.

303

The strength of this study was that it included GPs working in a range of settings and 304 305 locations within Australia. Our study should be read in light of some limitations. First, the 306 sample may not represent all GPs in Australia as it is prone to sampling bias and it is likely that participants who had some interest in sexual health were more likely to participate. For 307 308 instance, when comparing to the Australian GP population: we had a greater proportion of 309 female GPs (70.5% vs 49%), a younger cohort (most being 0-39yo 57% vs most 40-54yo 37%), and most in Victoria (39.3%) vs most in NSW (24%) (4). Another limitation is our use of 310 multiple choice questions, whereas qualitative responses may have provided a more 311 312 accurate assessment. Our question asking for participants to identify how to take PrEP could have been worded more clearly, as the answer 'taking a pill before and after an HIV 313 exposure, but only around the time of the exposure' could be interpreted as PrEP on 314 demand, however, it is technically not correct as it should specify taking 2 pills before an HIV 315 316 exposure. We adapted our knowledge questions from an Australian study (13) which utilises a TGA approved definition for how to take PrEP, whereas PrEP on-demand is a well accepted 317 method of taking PrEP that is not TGA approved. This could have affected the accuracy of 318 319 our assessment of GP knowledge.

320

321 CONCLUSION

Most of our GP participants were not confident in prescribing PrEP and had difficulty 322 323 identifying who would require PrEP. More GP specific training on PrEP is needed, focusing on PrEP knowledge, identifying suitable clients, and making it time efficient. The GPs should 324 be paid for the time to undertake this training. Further training is in itself insufficient, as the 325 wider issues facing General Practice need to be addressed, such as chronic under-funding 326 327 and no remuneration for training. Having questions about sexuality and the genders of sexual partners collected in registration forms could help GPs identify people who would 328 329 benefit from PrEP. GPs are well placed to dramatically increase the number and geographical coverage of PrEP prescribing, but they need further support. 330

331

332 Acknowledgements

The authors would like to thank the following organisations for help with distributing our survey: GPs Down Under (GPDU) Facebook Group, North Western Melbourne Primary Health Network, Brisbane North Primary Health Network, Victorian primary care practice-based Research and Education Network (VicREN), the University of Melbourne, Dr Richard Teague, Murray City Country Coast GP Training. We would also like to thank the researchers William Lane, Clare Heal and Jennifer Banks, for allowing us to utilise their Questionnaire from their study (13).

340 Conflicts of Interest

341 There are no other competing interests.

342

343 Declaration of Funding

DG is supported by a Canada Research Chair in Sexual and Gender Minority Health. EPFC and
JJO are each supported by an NHMRC Emerging Leadership Investigator Grant (GNT1172873
and GNT1193955, respectively). CKF is supported by an Australian NHMRC Leadership
Investigator Grant (GNT1172900).

349 Data statements

350 JO, EC and JW had full access to all of the data in the study. De-identified data is available on

Service UPH. PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE

- 351 reasonable request to the corresponding author.
- 352

354

353 **REFERENCES**

1.

355 UNITED STATES - 2017 UPDATE A CLINICAL PRACTICE GUIDELINE. 2017. 356 Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-2. 357 tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci 358 Transl Med. 2012;4(151):151ra25. 359 3. UNAIDS. Ending inequalities and getting on track to end AIDS by 2030. [Available from: 360 https://www.unaids.org/sites/default/files/media asset/2021-political-declaration summary-10-361 targets en.pdf#:~:text=Ensure%20availability%20of%20PrEP%20for%20%2810%20million%29%20pe 362 ople,appropriate%2C%20prioritized%2C%20peoplecentred%20and%20effective%20combination%20prevention%20options. 363 DHAC. General Practice Workforce (2017-2018 to 2022-2023 Financial Years). In: Care DoHA, 364 4. 365 editor. 2017-2018 to 2022-2023. Australasian Society for HIV VHaSHMA. ASHM Prescriber Map 2024 [Available from: 366 5. 367 https://www.ashm.org.au/prescriber-maps/. 368 Health AGDo. Sexual health Medicine - 2016 factsheet 2016 [Available from: 6. 369 https://hwd.health.gov.au/resources/publications/factsheet-mdcl-sexual-health-2016.pdf. 370 Fraser D MN, McManus H, Guy R, Grulich AE, Bavinton BR. Monitoring HIV pre-exposure 7. 371 prophylaxis (PrEP) uptake in Australia (Issue 8). Sydney: Kirby Institute, UNSW Sydney; 2023 ISSN: 372 2653-3820. 2023. 373 Smith AKJ, Haire B, Newman CE, Holt M. Challenges of providing HIV pre-exposure 8. 374 prophylaxis across Australian clinics: qualitative insights of clinicians. Sex Health. 2021;18(2):187-94. 375 Vanhamel J, Reyniers T, Wouters E, van Olmen J, Vanbaelen T, Nöstlinger C, et al. How Do 9. 376 Family Physicians Perceive Their Role in Providing Pre-exposure Prophylaxis for HIV Prevention?-An 377 Online Qualitative Study in Flanders, Belgium. Frontiers in Medicine. 2022;9. 378 10. Villeneuve F, Cabot JM, Eymard-Duvernay S, Visier L, Tribout V, Perollaz C, et al. Evaluating 379 family physicians' willingness to prescribe PrEP. Med Mal Infect. 2020;50(7):606-10. 380 Rai B, Ross S, Richardson D. P051 General practitioners' (GPs') knowledge of and attitudes to 11. 381 prescribing pre-exposure prophylaxis for HIV (PrEP): A pilot study. BMJ Publishing Group Ltd; 2021. Chiarabini T, Lacombe K, Valin N. HIV pre-exposure chemoprophylaxis "PrEP" in general 382 12. 383 practice: are there significant barriers? Sante Publique. 2021;33(1):101-12. 384 13. Lane W, Heal C, Banks J. HIV pre-exposure prophylaxis: Knowledge and attitudes among 385 general practitioners. Aust J Gen Pract. 2019;48(10):722-7. 386 14. Lazarou M, Fitzgerald L, Warner M, Downing S, Williams OD, Gilks CF, et al. Australian 387 interdisciplinary healthcare providers' perspectives on the effects of broader pre-exposure 388 prophylaxis (PrEP) access on uptake and service delivery: a qualitative study. Sex Health. 389 2020;17(6):485-92. 390 15. Monde Md. THE KAP SURVEY MODEL (KNOWLEDGE, ATTITUDES, & PRACTICES)2011 391 17/01/24. Available from: https://www.spring-nutrition.org/publications/tool-summaries/kap-392 survey-model-knowledge-attitudes-and-practices.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.24.24301757; this version posted January 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 393 16. Wu J FC, Grace D, Chow EPF, Ong JJ. Agreement of and discussion with clients about 394 Undetectable equals Untransmissible (U=U) among General Practitioners in Australia: A cross-
- 395 sectional survey. Sexual Health CSIRO. 2023; In Press.
- 396 17. ASHM. 2021 National PrEP guidelines. 2021 26/03/23.
- 397 18. King J, McManus, H, Kwon, A, Gray, R & McGregor, S. HIV, viral hepatitis and sexually 398 transmissible infections in Australia: Annual surveillance report 2022. Sydney, Australia: UNSW 399 Sydney; 2022.
- 400 Vanhamel J, Reyniers T, Wouters E, van Olmen J, Vanbaelen T, Nöstlinger C, et al. How Do 19.
- 401 Family Physicians Perceive Their Role in Providing Pre-exposure Prophylaxis for HIV Prevention?-An
- 402 Online Qualitative Study in Flanders, Belgium. Frontiers in Medicine. 2022;9:699.
- 403 20. Payne H. The new RACGP gender and sex standards, explained 2021 [Available from:
- 404 https://www.medicalrepublic.com.au/the-new-racgp-gender-and-sex-standards-explained/57824.
- 405 21. Holden L, Williams ID, Patterson E, Smith JW, Scuffham PA, Cheung L, et al. Uptake of
- 406 Medicare chronic disease management incentives - a study into service providers' perspectives. Aust 407 Fam Physician. 2012;41(12):973-7.
- Ahmed K HS, Khankhara M, et al. What drives general practitioners in the UK to improve the 408 22.
- 409 quality of care? A systematic literature review. BMJ Open Quality. 2021;10(1).